Ghrelin plays also a role in long-term body weight regulation, acting as an adiposity signal, communicating the state of energy stores to the brain

Consequently, companies such as Novo Nordisk and Eli Lilly are investing heavily in next-generation formulations, including oral small-molecule GLP-1 receptor agonists such as orforglipron, which aim to expand patient accessibility and therapeutic scope The demand for GLP-1 drugs that address a wider array of metabolic conditions is growing rapidly across global markets, as patients and healthcare providers increasingly seek holistic and effective long-term treatment options for obesity and its comorbidities GLP-1 Receptor Agonists Obesity Drugs Market Dynamics Driver Surging Demand Due to Rising Obesity Prevalence and Enhanced Clinical Outcomes The global surge in obesity rates and associated comorbidities such as type 2 diabetes and cardiovascular diseases is significantly driving demand for GLP-1 receptor agonist drugs as effective medical weight loss therapies For instance, in May 2024, Novo Nordisk announced a USD 4.1 billion expansion in its U.S

A lower energy intake makes it more challenging to consume sufficient protein (5)
Now, for millions, that signal is being switched off
Ive talked about the upsides of pharmacologically boosting GLP-1 activity in terms of weight loss, given the ravages of obesity, and Ive also discussed its downsides, including common gastrointestinal reactions and muscle loss, as well as the rarer or more speculative side effects such as thyroid cancer, pancreatitis, and pancreatic cancer
That's not a feature in the fine print it's a fundamental pharmacological difference